Prognostic Model Based on M6A-associated LncRNAs in Esophageal Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Sep 16

PMID 36111294

Authors

Weidong Wang

Danhong Dong

Pengfei Yu

Tong Chen

Ruiqi Gao

Jiangpeng Wei

Zhenchang Mo

Haikun Zhou

Qinchuan Yang

Chao Yue

Xisheng Yang

Xiaohua Li

Gang Ji

Affiliations

Soon will be listed here.

Abstract

Background: This research aimed to build an m6A-associated lncRNA prognostic model of esophageal cancer that can be used to predict outcome in esophageal cancer patients.

Methods: RNA sequencing transcriptome data and clinical information about patients with esophageal cancer were obtained according to TCGA. Twenty-four m6A-associated genes were selected based on previous studies. m6A-associated lncRNAs were determined through Pearson correlation analysis. Three m6A-associated lncRNA prognostic signatures were built through analysis of the training set using univariate, LASSO, and multivariate Cox regression. To validate the stabilization of the risk signature, Kaplan-Meier and ROC curve analyses were performed on the testing and complete sets. The prognoses of EC patients were predicted quantitatively by building a nomogram. GSEA was conducted to analyze the underlying signaling pathways and biological processes. To identify the underlying mechanisms through which the lncRNAs act, we constructed a PPI network and a ceRNA network and conducted GO and KEGG pathway analyses. EC samples were evaluated using the ESTIMATE algorithm to compute stromal, immune, and estimate scores. The ssGSEA algorithm was used to quantitatively infer immune cell infiltration and immune functions. The TIDE algorithm was performed to simulate immune evasion and predict the response to immunotherapy.

Results: We identified and validated an m6A-associated lncRNA risk model in EC that could correctly and reliably predict the OS of EC patients. The ceRNA network, PPI network, and GO and KEGG pathway analyses confirmed and the underlying mechanisms and functions provided enlightenment regarding therapeutic strategies for EC. Immunotherapy responses were better in the low-risk subgroup, and PD-1 and CTLA4 checkpoint immunotherapy benefited the patients in the low-risk subgroup.

Conclusions: We constructed a new m6A-related lncRNA prognostic risk model of EC, based on three m6A-related lncRNAs: LINC01612, AC025166.1 and AC016876.2, that can predict the prognoses of EC patients.

Citing Articles

RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints.

Qin X, Liu H, Zhang Q, Che Y, Lei T, Tang F Front Immunol. 2024; 15:1463847.

PMID: 39372415 PMC: 11449722. DOI: 10.3389/fimmu.2024.1463847.

Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells.

Dou Z, Ma X, Piao M, Wang J, Li J Transl Cancer Res. 2024; 13(6):3106-3125.

PMID: 38988908 PMC: 11231769. DOI: 10.21037/tcr-23-2401.

Editorial: The RNA revolution and cancer.

Dlamini Z, Ladomery M, Kahraman A Front Endocrinol (Lausanne). 2024; 15:1422599.

PMID: 38832352 PMC: 11144892. DOI: 10.3389/fendo.2024.1422599.

In Search of a Function for the N6-Methyladenosine in Epitranscriptome, Autophagy and Neurodegenerative Diseases.

Suga N, Ikeda Y, Yoshikawa S, Taniguchi K, Sawamura H, Matsuda S Neurol Int. 2023; 15(3):967-979.

PMID: 37606395 PMC: 10443253. DOI: 10.3390/neurolint15030062.

References

Huang T, Fu L . The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019; 39(1):79. PMC: 6878621. DOI: 10.1186/s40880-019-0427-z. View

Quinn J, Chang H . Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2015; 17(1):47-62. DOI: 10.1038/nrg.2015.10. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

Tan D, Wu Y, Hu L, He P, Xiong G, Bai Y . Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. Dis Esophagus. 2016; 30(1):1-9. DOI: 10.1111/dote.12481. View

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y . N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011; 7(12):885-7. PMC: 3218240. DOI: 10.1038/nchembio.687. View

Hoshida Y, Brunet J, Tamayo P, Golub T, Mesirov J . Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One. 2007; 2(11):e1195. PMC: 2065909. DOI: 10.1371/journal.pone.0001195. View

Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View

Zhou K, Shi H, Lyu R, Wylder A, Matuszek Z, Pan J . Regulation of Co-transcriptional Pre-mRNA Splicing by mA through the Low-Complexity Protein hnRNPG. Mol Cell. 2019; 76(1):70-81.e9. PMC: 6778029. DOI: 10.1016/j.molcel.2019.07.005. View

Liang Y, Chen X, Wu Y, Li J, Zhang S, Wang K . LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ. 2018; 25(11):1980-1995. PMC: 6219493. DOI: 10.1038/s41418-018-0084-9. View

10.

Agarwal V, Bell G, Nam J, Bartel D . Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015; 4. PMC: 4532895. DOI: 10.7554/eLife.05005. View

11.

Hosono Y, Niknafs Y, Prensner J, Iyer M, Dhanasekaran S, Mehra R . Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell. 2017; 171(7):1559-1572.e20. PMC: 5734106. DOI: 10.1016/j.cell.2017.11.040. View

12.

Zhao H, Xu Y, Xie Y, Zhang L, Gao M, Li S . m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer. Front Cell Dev Biol. 2021; 9:650023. PMC: 7970005. DOI: 10.3389/fcell.2021.650023. View

13.

Zhang M, Bai M, Wang L, Lu N, Wang J, Yan R . Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer. Cancer Cell Int. 2021; 21(1):114. PMC: 7887820. DOI: 10.1186/s12935-021-01747-9. View

14.

Wong N, Wang X . miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2014; 43(Database issue):D146-52. PMC: 4383922. DOI: 10.1093/nar/gku1104. View

15.

Schwartz M, Zhang Y, Rosenblatt J . B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer. 2016; 4:40. PMC: 4950763. DOI: 10.1186/s40425-016-0145-x. View

16.

Yang Y, Hsu P, Chen Y, Yang Y . Dynamic transcriptomic mA decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018; 28(6):616-624. PMC: 5993786. DOI: 10.1038/s41422-018-0040-8. View

17.

Zhang H, Hua Y, Jiang Z, Yue J, Shi M, Zhen X . Cancer-associated Fibroblast-promoted LncRNA Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2018; 25(6):1989-2000. DOI: 10.1158/1078-0432.CCR-18-0773. View

18.

Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z . The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021; 6(1):74. PMC: 7897327. DOI: 10.1038/s41392-020-00450-x. View

19.

Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J . METTL3-mediated mA modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2019; 69(7):1193-1205. DOI: 10.1136/gutjnl-2019-319639. View

20.

Chen X, Huang L, Yang T, Xu J, Zhang C, Deng Z . METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression. Front Oncol. 2021; 11:667451. PMC: 8170325. DOI: 10.3389/fonc.2021.667451. View